Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-Frederick

March 26, 2024 updated by: National Cancer Institute (NCI)

Collection and Distribution of Samples From Healthy Donors for In Vitro Research at NCI-Frederick

Background

-NCI-Frederick scientists performing in vitro studies involving human specimens have a need for a reliable and consistent source of samples which protects the donor from research risks.

Objective

-The purpose of this protocol is to establish a centralized repository for the collection and distribution of samples (either blood, buccal mucosal cells, semen, urine, or nail clippings) from paid, healthy volunteer donors for in vitro research conducted by NIH investigators located at NCI-Frederick and Ft. Detrick. Research will include, but are not limited to, genotype analysis, immune function studies, drug screening, vaccine development, method development, quality control testing of reagents, and propagation of infectious agents, including HIV.

Eligibility:

Healthy NCI-Frederick employees and other NIH staff located at Ft. Detrick will be recruited. Potential donors will be excluded if screening indicates exposure to HIV, HTLV, Hepatitis C or Hepatitis B virus infection.

Study Design:

Investigators requesting to participate to the Research Donor Program (RDP) by receiving samples for research use will be required to submit a written memo of request, briefly describing the nature of the research and providing assurance that samples provided through this protocol will be used solely for in vitro research.

These Investigators will receive samples that will be either anonymous or coded, depending on the specific need.

Codes will be securely maintained and under no circumstances will donor identity be released to Investigators.

Donors will receive financial compensation for their time, discomfort and inconvenience according to an established schedule; compensation for blood donation is based on the volume donated.

Study Overview

Status

Enrolling by invitation

Conditions

Detailed Description

Background

-NCI-Frederick scientists performing in vitro studies involving human specimens have a need for a reliable and consistent source of samples which protects the donor from research risks.

Objective

-The purpose of this protocol is to establish a centralized repository for the collection and distribution of samples (either blood, buccal mucosal cells, semen, urine, or nail clippings) from paid, healthy volunteer donors for in vitro research conducted by NIH investigators located at NCI-Frederick and Ft. Detrick. Research will include, but are not limited to, genotype analysis, immune function studies, drug screening, vaccine development, method development, quality control testing of reagents, and propagation of infectious agents, including HIV.

Eligibility:

Healthy NCI-Frederick employees and other NIH staff located at Ft. Detrick will be recruited. Potential donors will be excluded if screening indicates exposure to HIV, HTLV, Hepatitis C or Hepatitis B virus infection.

Study Design:

Investigators requesting to participate to the Research Donor Program (RDP) by receiving samples for research use will be required to submit a written memo of request, briefly describing the nature of the research and providing assurance that samples provided through this protocol will be used solely for in vitro research.

These Investigators will receive samples that will be either anonymous or coded, depending on the specific need.

Codes will be securely maintained and under no circumstances will donor identity be released to Investigators.

Donors will receive financial compensation for their time, discomfort and inconvenience according to an established schedule; compensation for blood donation is based on the volume donated.

Study Type

Observational

Enrollment (Estimated)

1200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Frederick, Maryland, United States, 21702-1201
        • NCI Frederick Cancer Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Healthy NCI Frederick Cancer Research and Development Center employees@@@@@@

Description

  • INCLUSION CRITERIA:

Individuals must meet the following eligibility criteria to be entered into the RDP donor pool, as follows:

  1. Age 18 or older.
  2. Weight of 110 lb or greater.
  3. All subjects must have the ability and agree to participate fully and comply with the procedures of the protocol and provide informed consent.
  4. Registration for participation in semen donation is limited to males currently enrolled in the donor pool.
  5. Subjects must be NCI Frederick Employees

EXCLUSION CRITERIA:

Individuals with any of the following will be excluded from the donor pool:

  1. History of chronic illness that might increase the risks associated with phlebotomy, including but not limited to heart, lung, or kidney disease
  2. Current acute illness.
  3. History of clotting disorders.
  4. Current medications which might increase the risk associated with phlebotomy.
  5. History of syncope or other difficulty with venipuncture.
  6. Anemia, as determined by hematocrit or hemoglobin.

    Hemotacrit acceptable range for males: 40-51 percent.

    Hemotacrit acceptable range for females: 34-46 percent.

  7. Hemoglobin acceptable range for males: 12.5-17.0 g/dl

    Hemoglobin acceptable range for females: 11.5-15.2 g/dl

  8. Positive blood test for exposure to HIV-1, HIV-2, HTLV-1, HTLV-2, or HCV or for HBV surface antigens.
  9. Individuals whose activities or conditions place them at high risk of HIV infection are asked not to donate.
  10. Males who qualify for participation in the donor pool will be excluded from participation in semen donation if they have knowingly had any injury, infection, or treatment performed that renders them incapable of producing sperm.
  11. Pregnancy: Pregnant women will not be allowed to enroll in this study because there is no benefit.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
1/ single cohort
Healthy NCI Frederick Cancer Research and Development Center employees

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Establish a centralized repository for the collection and distribution ofsamples
Time Frame: Ongoing
Collection of biospecimens
Ongoing

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Janelle Cortner, Ph.D., National Cancer Institute (NCI)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 1999

Primary Completion (Estimated)

October 1, 2030

Study Completion (Estimated)

October 13, 2030

Study Registration Dates

First Submitted

June 19, 2006

First Submitted That Met QC Criteria

June 19, 2006

First Posted (Estimated)

June 21, 2006

Study Record Updates

Last Update Posted (Actual)

March 27, 2024

Last Update Submitted That Met QC Criteria

March 26, 2024

Last Verified

September 26, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 999999046
  • OH99-C-N046

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Donors

3
Subscribe